Table 4.
Adverse events
| n (%) | Total
|
First-cesarean
|
Repeat-cesarean
|
||||||
|---|---|---|---|---|---|---|---|---|---|
| With LB-TAPB (n=101) | Without LB-TAPB (n=100) | P-valuea | With LB-TAPB (n=34) | Without LB-TAPB (n=56) | P-valuea | With LB-TAPB (n=67) | Without LB-TAPB (n=44) | P-valuea | |
|
| |||||||||
| Patients with ≥1 AE | n=101 | n=93 | 0.026 | n=34 | n=51 | 0.240 | n=67 | n=42 | 0.036 |
| 34 (33.7) | 46 (49.5) | 11 (32.4) | 23 (45.1) | 23 (34.3) | 23 (54.8) | ||||
| ORAEs of interest | n=43 | n=76 | 0.305 | n=13 | n=35 | 0.988 | n=30 | n=41 | 0.252 |
| Nausea | 16 (37.2) | 38 (50.0) | 6 (46.2) | 17 (48.6) | 10 (33.3) | 21 (51.2) | |||
| Pruritus | 19 (44.2) | 30 (39.5) | 5 (38.5) | 13 (37.1) | 14 (46.7) | 17 (41.5) | |||
| Vomiting | 7 (16.3) | 8 (10.5) | 2 (15.4) | 5 (14.3) | 5 (16.7) | 3 (7.3) | |||
| Abdominal pain | 1 (2.3) | 0 | 0 | 0 | 1 (3.3) | 0 | |||
Note:
a
P-value was calculated using chi-squared test.
Abbreviations: AE, adverse event; LB-TAPB, transversus abdominis plane block with liposomal bupivacaine; ORAEs, opioid-related adverse events.